Browse the evidence

Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.

If a child or young adult is diagnosed with diabetes, ask if genetic testing for monogenic forms has been considered. Misdiagnosis as T1 or T2 can lead to incorrect treatment and worse outcomes, as monogenic diabetes often requires specific therapies different from standard insulin or oral agents.

Machine learning-guided optimization of triple agonist peptides (GCGR, GLP1R, GIPR) using Graph Attention Networks and genetic algorithms generates peptide sequences with high predicted binding affinity across all three targets, demonstrating superior computational performance over traditional Convolutional Neural Networks for GCGR prediction.

This research does not yet offer a direct treatment for patients. It describes a computational method to design better diabetes and obesity drugs. The key takeaway is that using advanced AI (Graph Attention Networks) to design peptides that target three metabolic receptors (GCGR, GLP1R, GIPR) simultaneously is more effective than older methods. This could lead to more potent drugs in the future, but no such drug is currently available for clinical use based on this paper alone.

Knockout of the lineage-specific microprotein Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation by approximately 50% in 3T3-L1 cells.

This research identifies a specific microprotein (Adipocyte-smORF-1183) in mouse fat cells that helps store fat. Knocking it out reduces fat storage by half in these cells. This is a basic science discovery about how fat cells work and does not currently translate to a human treatment or supplement.

Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.

If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.

1.2% of boys and men aged 15 to 35 reported use of prescription weight loss medication in the past 12 months.

Practitioners should be aware of the low prevalence of prescription weight loss medication use in this demographic.

Inhibiting miR-30e-5p using antagomirs reduces atherosclerosis in obese mouse models by restoring SLC7A11 expression and improving endothelial mitochondrial function.

While not yet a human treatment, this finding suggests that future therapies could target the specific signals fat cells send to blood vessels. For now, maintaining a healthy weight remains the most effective way to prevent these damaging signals from accumulating.

Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.

If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.

There is insufficient evidence to support a causal relationship between GLP-1 receptor agonists and the risk of other common mental illnesses, including ADHD, Anorexia Nervosa, Autism Spectrum Disorder, and PTSD.

Based on this genetic study, GLP-1 drugs do not appear to reduce the risk of ADHD, Anorexia, Autism, or PTSD. Patients with these conditions should not rely on GLP-1 medications as a treatment for their mental health symptoms. Further research is needed to confirm these negative findings.

Current clinical practice for prescribing semaglutide for weight loss lacks comprehensive pretreatment screening for thyroid, pancreatic, and retinal risks, exposing patients to severe adverse outcomes.

If you are starting semaglutide for weight loss, ensure your doctor checks your calcitonin, pancreatic enzymes (lipase/amylase), and family history of thyroid cancer before starting. Standard blood tests are not enough to rule out serious risks associated with this medication.

Biomechanically calculated repair (BCR) using GRIP/CRIP concepts significantly reduces hernia recurrence rates compared to conventional repair techniques.

For complex hernias, ask if your surgeon uses biomechanical planning (GRIP/CRIP). This method tests how your abdominal wall handles daily stress before surgery, leading to a repair that is much less likely to fail (recurrence) compared to standard techniques. It may require a specialized center, but the long-term success rate is significantly higher.

Botulinum toxin A (BTA) injections and Progressive Preoperative Pneumoperitoneum (PPP) are effective mechanical optimization strategies for loss-of-domain hernias, reducing fascial tension and enabling primary closure.

If you have a very large hernia where the organs have slipped out of the abdominal cavity for a long time, standard surgery might be too risky. Your surgeon might recommend Botox injections to relax your abdominal muscles or a process called PPP (pumping air into your abdomen) to stretch your muscles before surgery. This makes it possible to close the hernia without major cutting, reducing recovery time and complications.